TCGA-BT-A20U-01A-11R-A14Y-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 14.94743758
- os_event
- true
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.560
- G2M_CHECKPOINT+0.520
- E2F_TARGETS+0.510
- MTORC1_SIGNALING+0.470
- MYC_TARGETS_V2+0.440
- ANDROGEN_RESPONSE+0.430
- MITOTIC_SPINDLE+0.430
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.400
- UNFOLDED_PROTEIN_RESPONSE+0.370
- OXIDATIVE_PHOSPHORYLATION+0.350
Top 10 suppressed
- PANCREAS_BETA_CELLS-0.320
- KRAS_SIGNALING_DN-0.200
- INTERFERON_ALPHA_RESPONSE-0.190
- IL6_JAK_STAT3_SIGNALING-0.120
- MYOGENESIS-0.110
- SPERMATOGENESIS-0.090
- INTERFERON_GAMMA_RESPONSE-0.080
- BILE_ACID_METABOLISM-0.050
- TNFA_SIGNALING_VIA_NFKB-0.050
- ALLOGRAFT_REJECTION-0.040
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG252 | — | — | 0.883 |
| 2 | BDEB76B7-B7E0-4058-82A2-77E93748C936 | — | — | 0.870 |
| 3 | TCGA-FD-A6TH-01A-11R-A32O-07 | — | — | 0.863 |
| 4 | TCGA-85-7843-01A-11R-2125-07 | — | cohortSQ1 | 0.856 |
| 5 | TCGA-56-7222-01A-11R-2045-07 | — | cohortSQ1 | 0.849 |
| 6 | SRR934967 | — | — | 0.841 |
| 7 | MNG544 | — | — | 0.835 |
| 8 | TCGA-K4-A5RI-01A-11R-A28M-07 | — | — | 0.822 |
| 9 | 28B7B2FC-8270-42E3-95ED-4CC4F0979EE9 | — | — | 0.820 |
| 10 | TCGA-21-1071-01A-01R-0692-07 | — | cohortSQ2 | 0.819 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 36 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.560 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.520 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.510 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.470 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.440 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.430 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.430 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.400 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.370 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.350 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.350 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.330 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.290 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.290 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.280 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.270 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.260 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.230 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.220 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.190 | Inavolisib | — uncovered |